Michael Oberst
Overview
Explore the profile of Michael Oberst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Afshar M, Resnik F, Baumann M, Hintzke J, Sullivan A, Shah T, et al.
medRxiv
. 2025 Jan;
PMID: 39763559
Background: Ambient artificial intelligence offers promise for improving documentation efficiency and reducing provider burden through clinical note generation. However, challenges persist in workflow integration, compliance, and widespread adoption. This study...
2.
Freeman P, Bellomo G, Ireland L, Abudula M, Luckett T, Oberst M, et al.
Front Immunol
. 2024 Aug;
15:1382538.
PMID: 39165364
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with an urgent unmet clinical need for new therapies. Using a combination of assays and preclinical models we demonstrate that therapeutic...
3.
Kurokawa C, Agrawal S, Mitra A, Galvani E, Burke S, Varshine A, et al.
Mol Ther Oncol
. 2024 Apr;
32(1):200758.
PMID: 38596304
Oncolytic viruses are engineered to selectively kill tumor cells and have demonstrated promising results in early-phase clinical trials. To further modulate the innate and adaptive immune system, we generated AZD4820,...
4.
Ji C, Oberst M, Kanjilal S, Sontag D
AMIA Jt Summits Transl Sci Proc
. 2021 Aug;
2021:305-314.
PMID: 34457145
Reinforcement learning (RL) has the potential to significantly improve clinical decision making. However, treatment policies learned via RL from observational data are sensitive to subtle choices in study design. We...
5.
El Meskini R, Atkinson D, Kulaga A, Abdelmaksoud A, Gumprecht M, Pate N, et al.
Mol Cancer Res
. 2021 Apr;
19(8):1422-1436.
PMID: 33888600
Only a subset of patients responds to immune checkpoint blockade (ICB) in melanoma. A preclinical model recapitulating the clinical activity of ICB would provide a valuable platform for mechanistic studies....
6.
Oberst M, Heinrich A
Unfallchirurg
. 2021 Feb;
124(5):362-365.
PMID: 33638014
Due to the airborne transmission of the coronavirus disease 2019 (COVID 19) via aerosols or microdroplets, this study investigated the effect of a mobile air filter system in a surgical...
7.
Schofield D, Percival-Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, et al.
MAbs
. 2021 Jan;
13(1):1857100.
PMID: 33397194
Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially...
8.
Kanjilal S, Oberst M, Boominathan S, Zhou H, Hooper D, Sontag D
Sci Transl Med
. 2020 Nov;
12(568).
PMID: 33148625
Antibiotic resistance is a major cause of treatment failure and leads to increased use of broad-spectrum agents, which begets further resistance. This vicious cycle is epitomized by uncomplicated urinary tract...
9.
Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, et al.
J Immunother Cancer
. 2019 Aug;
7(1):225.
PMID: 31439037
Background: The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. Methods: MEDI0680 was...
10.
Tigue N, Bamber L, Andrews J, Ireland S, Hair J, Carter E, et al.
Oncoimmunology
. 2017 Apr;
6(3):e1280645.
PMID: 28405505
Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) is part of a system of signals involved in controlling T-cell activation. Targeting and agonizing GITR in mice promotes antitumor immunity by enhancing...